Johnson & Johnson Reports Promising Results for Psoriasis Drug Icotrokinra in Adolescents

Johnson & Johnson announced on April 10, 2025, that its investigational oral therapy icotrokinra (JNJ-2113) showed high efficacy and a favorable safety profile in adolescents with moderate-to-severe plaque psoriasis. Data from the Phase 3 ICONIC-LEAD trial revealed that 75% of adolescents achieved completely clear skin (IGA 0) after 24 weeks of treatment with the once-daily pill.

In the same period, 86.4% achieved clear or almost clear skin (IGA 0/1), and 88.6% showed a 90% improvement in the Psoriasis Area and Severity Index (PASI 90). Additionally, 63.6% reached PASI 100, indicating full skin clearance. Adverse events were reported in 50% of patients on icotrokinra, compared to 73% on placebo, with no new safety issues identified.

Icotrokinra is a first-in-class oral peptide that selectively blocks the IL-23 receptor and is part of Johnson & Johnson’s broader ICONIC clinical program targeting both plaque psoriasis and psoriatic arthritis. The study included both adolescents and adults, marking the first registrational trial to simultaneously assess a systemic therapy across these groups.

The company emphasized the importance of early and effective treatment options for younger patients and highlighted icotrokinra’s potential to provide a convenient oral alternative with strong clinical outcomes.